J&J/McNeil Divests E.P.T. Pregnancy Tests To Insight Pharmaceuticals
This article was originally published in The Tan Sheet
Johnson & Johnson divests another non-core consumer health brand – e.p.t. pregnancy tests – as the remediation of its OTC business continues.
You may also be interested in...
Insight Pharmaceutical expanded its women’s health care footprint with the acquisition of the Monistat North American portfolio from McNeil Consumer Healthcare.
Johnson & Johnson reported July 19 the first period of positive growth for its consumer unit in more than a year.
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.